Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update
Provided By PR Newswire
Last update: Aug 7, 2025
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $107.4 Million for the Second Quarter of 2025, Reflecting 19% Growth Over the Second Quarter of 2024—
Read more at prnewswire.com
